Sialadenoma Papilliferum of the Bronchus: An Unrecognized Bronchial Counterpart of the Salivary Gland Tumor With Frequent BRAF V600E Mutations.

Szczegóły
Abstrakt

Tytuł:: Sialadenoma Papilliferum of the Bronchus: An Unrecognized Bronchial Counterpart of the Salivary Gland Tumor With Frequent BRAF V600E Mutations.
Autorzy:: Nakaguro M; Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya.; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Mino-Kenudson M; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Urano M; Department of Diagnostic Pathology, School of Medicine, Fujita Health University, Toyoake.
Ogawa I; Center of Oral Clinical Examination, Hiroshima University Hospital, Hiroshima.
Honda Y; Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto.
Hirai H; Departments of Anatomic Pathology.
Tanigawa M; Departments of Anatomic Pathology.
Sukeda A; Departments of Anatomic Pathology.
Kajiwara N; Surgery, Tokyo Medical University.
Ohira T; Surgery, Tokyo Medical University.
Ikeda N; Surgery, Tokyo Medical University.
Mikami Y; Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto.
Tada Y; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo.
Ikeda JI; Department of Diagnostic Pathology, Chiba University Graduate School of Medicine, Chiba, Japan.
Matsubayashi J; Departments of Anatomic Pathology.
Faquin WC; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Sadow PM; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Nagao T; Departments of Anatomic Pathology.
Źródło:: The American journal of surgical pathology [Am J Surg Pathol] 2021 May 01; Vol. 45 (5), pp. 662-671.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: <2015- > : Philadelphia, PA : Wolters Kluwer Health, Inc.
Original Publication: New York, Masson.
MeSH Terms:: Mutation*
Adenoma/*genetics
Biomarkers, Tumor/*genetics
Bronchial Neoplasms/*genetics
Proto-Oncogene Proteins B-raf/*genetics
Salivary Gland Neoplasms/*genetics
Adenoma/enzymology ; Adenoma/pathology ; Adenoma/surgery ; Aged ; Biomarkers, Tumor/analysis ; Biopsy ; Bronchial Neoplasms/enzymology ; Bronchial Neoplasms/pathology ; Bronchial Neoplasms/surgery ; DNA Mutational Analysis ; Diagnosis, Differential ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Predictive Value of Tests ; Salivary Gland Neoplasms/enzymology ; Salivary Gland Neoplasms/pathology ; Treatment Outcome
References:: Park CM, Goo JM, Lee HJ, et al. Tumors in the tracheobronchial tree: CT and FDG PET features. Radiographics. 2009;29:55–71.
Stevic R, Milenkovic B. Tracheobronchial tumors. J Thorac Dis. 2016;8:3401–3413.
Resio BJ, Chiu AS, Hoag J, et al. Primary salivary type lung cancers in the National Cancer Database. Ann Thorac Surg. 2018;105:1633–1639.
Falk N, Weissferdt A, Kalhor N, et al. Primary pulmonary salivary gland-type tumors: a review and update. Adv Anat Pathol. 2016;23:13–23.
Honda Y, Shiraishi K, Nomori H, et al. Sialadenoma papilliferum of the bronchus: rare tracheobronchial tumor of salivary gland type. Pathol Int. 2009;59:572–576.
Bobos M, Hytiroglou P, Karkavelas G, et al. Sialadenoma papilliferum of bronchus. Virchows Arch. 2003;443:695–699.
Campisi A, Dell’Amore A, Bertolaccini L, et al. Sialadenoma papilliferum of the bronchus: a rare tumour of salivary gland origin. Adv Respir Med. 2020;88:267–270.
Abrams AM, Finck FM. Sialadenoma papilliferum. A previously unreported salivary gland tumor. Cancer. 1969;24:1057–1063.
Foschini MP, Bell D, Katabi N El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. Sialadenoma papilliferum. WHO Classification of Head and Neck Tumours. Lyon, France: International Agency for Research on Cancer; 2017:192.
Nakaguro M, Urano M, Ogawa I, et al. Histopathological evaluation of minor salivary gland papillary-cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. Histopathology. 2020;76:411–422.
Maiorano E, Favia G, Ricco R. Sialadenoma papilliferum: an immunohistochemical study of five cases. J Oral Pathol Med. 1996;25:336–342.
Gera M, Tan A. Sialadenoma papilliferum arising in the nasal cavity: immunohistochemical analysis. Pathology. 2017;49:94–95.
Fowler CB, Damm DD. Sialadenoma papilliferum: analysis of seven new cases and review of the literature. Head Neck Pathol. 2018;12:193–201.
Hsieh MS, Bishop JA, Wang YP, et al. Salivary sialadenoma papilliferum consists of two morphologically, immunophenotypically, and genetically distinct subtypes. Head Neck Pathol. 2020;14:489–496.
Flieder DB, Nicholson AG, Travis WD, et al. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Papillomas. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: International Agency for Research on Cancer; 2015:106–109.
Flieder DB, Koss MN, Nicholson A, et al. Solitary pulmonary papillomas in adults: a clinicopathologic and in situ hybridization study of 14 cases combined with 27 cases in the literature. Am J Surg Pathol. 1998;22:1328–1342.
Huang YL, Chang YL, Chen KC, et al. Mixed squamous cell and glandular papilloma of the lung: a case report of a novel mutation in the BRAF gene and coexistent HPV infection, possible relationship to ciliated muconodular papillary tumor. Pathol Int. 2019;69:104–109.
Kitawaki Y, Fujishima F, Taniuchi S, et al. Coexistence of glandular papilloma and sclerosing pneumocytoma in the bronchiole. Pathol Int. 2018;68:425–430.
Lin DL, Xing XM, Ran WW, et al. Pulmonary peripheral glandular papilloma and mixed squamous cell and glandular papilloma frequently harbour the BRAF V600E mutation. Histopathology. 2020;76:997–1004.
Brannon RB, Sciubba JJ, Giulani M. Ductal papillomas of salivary gland origin: a report of 19 cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92:68–77.
Jones RT, Abedalthagafi MS, Brahmandam M, et al. Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. Mod Pathol. 2015;28:596–606.
Travis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: International Agency for Research on Cancer; 2015.
Aida S, Ohara I, Shimazaki H, et al. Solitary peripheral ciliated glandular papillomas of the lung: a report of 3 cases. Am J Surg Pathol. 2008;32:1489–1494.
Kamata T, Yoshida A, Kosuge T, et al. Ciliated muconodular papillary tumors of the lung: a clinicopathologic analysis of 10 cases. Am J Surg Pathol. 2015;39:753–760.
Chang JC, Montecalvo J, Borsu L, et al. Bronchiolar adenoma: expansion of the concept of ciliated muconodular papillary tumors with proposal for revised terminology based on morphologic, immunophenotypic, and genomic analysis of 25 cases. Am J Surg Pathol. 2018;42:1010–1026.
Kamata T, Sunami K, Yoshida A, et al. Frequent BRAF or EGFR mutations in ciliated muconodular papillary tumors of the lung. J Thorac Oncol. 2016;11:261–265.
Liu L, Aesif SW, Kipp BR, et al. Ciliated muconodular papillary tumors of the lung can occur in western patients and show mutations in BRAF and AKT1. Am J Surg Pathol. 2016;40:1631–1636.
May A, Tucker A. Understanding the development of the respiratory glands. Dev Dyn. 2015;244:525–539.
Taguchi R, Higuchi K, Sudo M, et al. A case of anaplastic lymphoma kinase (ALK)-positive ciliated muconodular papillary tumor (CMPT) of the lung. Pathol Int. 2017;67:99–104.
Jin Y, Shen X, Shen L, et al. Ciliated muconodular papillary tumor of the lung harboring ALK gene rearrangement: case report and review of the literature. Pathol Int. 2017;67:171–175.
Emoto K, Eguchi T, Tan KS, et al. Expansion of the concept of micropapillary adenocarcinoma to include a newly recognized filigree pattern as well as the classical pattern based on 1468 stage I lung adenocarcinomas. J Thorac Oncol. 2019;14:1948–1961.
Ide F, Kikuchi K, Kusama K, et al. Sialadenoma papilliferum with potentially malignant features. J Clin Pathol. 2010;63:362–364.
Shimoda M, Kameyama K, Morinaga S, et al. Malignant transformation of sialadenoma papilliferum of the palate: a case report. Virchows Arch. 2004;445:641–646.
Solomon MP, Rosen Y, Alfonso A. Intraoral papillary squamous cell tumor of the soft palate with features of sialadenoma papilliferum? malignant sialadenoma papilliferum. Cancer. 1978;42:1859–1869.
An AR, Park SY, Kim JH, et al. Adenocarcinoma-papillary cystic pattern arising in a mixed squamous and glandular papilloma of the lung. Int J Surg Pathol. 2020;28:658–662.
Grant Information:: P01 CA240239 United States CA NCI NIH HHS
Substance Nomenclature:: 0 (Biomarkers, Tumor)
EC 2.7.11.1 (BRAF protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
Entry Date(s):: Date Created: 20210114 Date Completed: 20210510 Latest Revision: 20230922
Update Code:: 20240105
PubMed Central ID:: PMC8035241
DOI:: 10.1097/PAS.0000000000001657
PMID:: 33443864
: Czasopismo naukowe

Sialadenoma papilliferum (SP) is a rare benign tumor of the salivary glands, and only 3 unequivocal cases of SP arising in the bronchus have been reported. We herein describe the histomorphologic and molecular features of 4 bronchial SP cases and discuss the differential diagnosis of this entity and the relationship with its clinicopathologic mimics, in particular, glandular papilloma and mixed squamous cell and glandular papilloma (GP/MP). We encountered 2 male and 2 female patients with bronchial SP (mean: 66.8 y old). All 4 tumors arose in the central bronchus and were characterized by a combination of surface exophytic endobronchial papillary proliferation and a submucosal multicystic component with complex architecture. The neoplastic epithelium consisted predominantly of nonciliated stratified columnar cells with ciliated, squamous, and mucinous cells present focally. While 2 tumors (50%) harbored a BRAF V600E mutation by molecular and immunohistochemical analysis, similar to GP/MP, no KRAS, HRAS, AKT1, or PIK3CA mutations were detected in any of the cases. Two patients were treated with limited resection, while 2 patients underwent lobectomy based on the diagnosis of adenocarcinoma or possible squamous cell carcinoma in situ in the preoperative biopsy. All survived without recurrence or metastasis for 23 to 122 months after treatment. SP can develop in the central bronchus as the bronchial counterpart of the salivary gland tumor and should be considered in the differential diagnosis of endobronchial tumors. In addition, some histologic resemblance and frequent BRAF V600E mutation raise the possibility of SP and GP/MP being on the same disease spectrum.
Competing Interests: Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
(Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Informacja